Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.

Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-Justo M, Yong KL.

Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.

PMID:
27313079
2.

Targeting B-cell maturation antigen in multiple myeloma.

Tai YT, Anderson KC.

Immunotherapy. 2015;7(11):1187-99. doi: 10.2217/imt.15.77. Epub 2015 Sep 15. Review.

3.

B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

Hengeveld PJ, Kersten MJ.

Blood Cancer J. 2015 Feb 27;5:e282. doi: 10.1038/bcj.2015.3. Review.

4.

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC.

Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25.

Supplemental Content

Loading ...
Support Center